Mergers & Acquisitions ·
Drugs Made In America Acquisition Corp. approved a third amendment to its merger agreement with Power Analytics Global…
DMAADrugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. approved a third amendment to its merger agreement with Power Analytics Global Corp. Key changes include the former sponsor forfeiting at least 50% of founder shares and surrendering 430,000 private placement rights. The company will initiate a cash tender offer for publicly held rights at $0.25 to $0.35 per right, or an exchange offer or consent solicitation. The amendment also establishes a target minimum cash of $30 million and a floor of $15 million, and introduces a potential three-party business combination contingent on a letter of intent by September 30, 2026. This is a special purpose acquisition company (SPAC) operating in the healthcare and technology sectors.